Status:
COMPLETED
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
Lead Sponsor:
Forest Laboratories
Conditions:
Hypertension
Eligibility:
All Genders
18-79 years
Phase:
PHASE4
Brief Summary
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.
Eligibility Criteria
Inclusion
- male and female outpatients 18 to 79 years of age
- Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen
- meet criteria for stage I or II hypertension
- currently not treated, or being treated with no more than two anti-hypertensive medications
Exclusion
- type 1 or type 2 diabetes
- secondary hypertension
- evidence of other concurrent disease or conditions that might interfere with the conduct of the study
- treatment with any investigational study drug within 30 days of Screening (Visit 1)
- have a history of hypersensitivity to nebivolol or other β-blockers
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00785512
Start Date
November 1 2008
Last Update
September 15 2010
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Chandler, Arizona, United States, 85225
2
Forest Investigative Site
Phoenix, Arizona, United States, 85050
3
Forest Investigative Site
Los Angeles, California, United States, 90057
4
Forest Investigative Site
Bradenton, Florida, United States, 34203